资源描述：
《补肾益髓法治疗中间型珠蛋白合成障碍性贫血临床研究》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。
1、医学研究杂志2010年10月第39卷第10期·论著·补肾益髓法治疗中间型珠蛋白合成障碍性贫血临床研究方素萍张新华吴志奎王文娟刘咏梅李敏王荣新柴立民张冲陈玉英吕鑫霞摘要目的探讨补肾益髓法从肾论治治疗两种不同类型(α-,β-型)中间型珠蛋白合成障碍性贫血的临床疗效。方法选取具有相同中医证候(肝肾阴虚,精血不足证),不同基因型的两种中间型地中海贫血患者(α-,β-型),用补肾益髓法的代表方益髓生血颗粒进行治疗,疗程3个月,采用自身对照方法,动态观察患者疗效性血液指标Hb、RBC、Ret、HbH的变化。结果益髓生血
2、颗粒治疗中间型β-地中海贫血96例,有效78例,无效17例,有效率81.3%。有效病例患者的血液指标(Hb、RBC、Ret、HbF),自治疗第1个月起至3个月疗程结束均明显升高(均P<0.01);治疗中间型α-HbH病81例,有效62例,无效18例,有效率76.5%。有效病例患者临床血液指标Hb、RBC、Ret,自第1个月起至3个月疗程结束均明显升高(P<0.01)。益髓生血颗粒治疗中间型地中海盆血总有效率为79.1%,β-地中海贫血和α-HbH病的疗效差异无统计学意义,服药后患者临床症状的明显改善与血液学
3、指标的提高相一致。结论补肾益髓法治疗相同中医证候(肝肾阴虚精血不足证)不同基因型的(β-地中海贫血,α-HbH病)两种类型的中间型地中海贫血患者,均有明显疗效。关键词珠蛋白合成障碍性贫血中间型(α-,β-型)中医证候补肾益髓法益髓生血颗粒ClinicalStudiesofKidneyTonifyingTherapyonIntermediaThalassemia.FangSuping,ZhangXinhua,WuZhikui,WangWenjuan,LiuYongmei,LiMin,WangRongxin,C
4、haiLimin,ZhangChong,ChenYuying,LüXinxia.DepartmentofMolecular-Biology,Guang′AnMenHospital,ChinaAcademyofTraditionalChineseMedicine,Beijing100053,ChinaAbstractObjectiveTostudytheTraditionalChineseMedicineTheory“KidneyEngendersMarrow”bytreatingtwogenotypesin
5、2termediathalassemia(bothα-andβ-)patientswithkidneytonifyingformula.MethodsSelf-cross-referredtrialswereusedintreatingtwogenotypesintermediathalassemiapatients(bothαandβtypesdiagnosedasDeficiencyofYinofbothLiverandKidneyandastheniaofessenceandbloodinTCMmet
6、hods)inhigherfrequencyprovinceofGuangxiwithYiSuiShengXueGranule(YSSXG)for3months.TheHb,RBC,RetandHbHlevelchangesweredetecteddynamicallyeverymonth.ResultsIn96casesofβ-thalassemiapa2tientstreatedwithYSSXG,78caseswereeffective,17caseswereineffective,andtheeff
7、ectiveratewas81.3%.Thelevelsofbloodinde2xesincludingHb,RBC,RetandHbFweresignificantlyenhancedfromthefirstmonthtothethirdmonthinthosebeta-thalassemiaeffec2tivecases(P<0.01).Andin81casesofα-thalassemiapatientstreatedwithYSSXG,62caseswereeffective,18caseswere
8、ineffec2tive,andtheeffectiveratewas76.5%.ThelevelsofHb,RBCandRetweresignificantlyenhancedfromthefirstmonthtothethirdmonthinthosebeta-thalassemiaeffectivecases(P<0.01).Thetotaleffectiveratewas79.1%.Nostatistic
